CTOs on the Move


 
Endo International plc is a highly focused generics and specialty pharmaceutical company delivering quality medicines through excellence in development, manufacturing and commercialization. Through our operating companies – Endo Pharmaceuticals, Par Pharmaceutical and Paladin Labs – Endo is dedicated to serving patients in need. Endo commenced operations in 1997 by acquiring certain pharmaceutical products, related rights and assets from The DuPont Merck Pharmaceutical Company. Since that time, the company has expanded to include the following business segments: U.S. Branded Pharmaceuticals, U.S. Generic Pharmaceuticals and International Pharmaceuticals. Endo`s strategy is to centralize and unify our business, driving productivity improvements. We will focus ...
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion
  • www.endo.com
  • 1400 Atwater Drive
    Malvern, PA USA 19355
  • Phone: 484.216.0000

Executives

Name Title Contact Details
Cheryl Stouch
Senior Vice President, Information Technology and Chief Information Officer Profile
Mark Gaines
Associate Director, IT Security and Infrastructure Profile

Jobs

Similar Companies

Bright Pharmaceutical Services

Bright Pharmaceutical Services is a Sherman Oaks, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Travanti Pharma

Travanti Pharma is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ion Labs

Ion Labs is a cGMP Certified & FDA registered private label and contract manufacturer of dietary supplements, OTCs, pet supplements, and skin care products.

Coeptis Therapeutics

Coeptis Therapeutics Holdings, Inc., together with its subsidiaries including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals, Inc., (collectively "Coeptis"), is a biopharmaceutical company developing innovative cell therapy platforms for cancer that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. Coeptis` product portfolio and rights are highlighted by a universal, multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), and intellectual property and knowhow related to the GEAR™ cell therapy and companion diagnostic platforms, which Coeptis is developing with VyGen-Bio and leading medical researchers at the Karolinska Institutet. Coeptis` business model is designed around maximizing the value of its current product portfolio and rights through in-license agreements, out-license agreements and co-development relationships, as well as entering into strategic partnerships to expand its product rights and offerings, specifically those targeting cancer. The Company is headquartered in Wexford, PA.

Evergreen Theragnostics

Evergreen Theragnostics was established in 2019 to be a leading US-based radiopharmaceutical Contract Development and Manufacturing Organization (CDMO).